Medicine & Pharmaceuticals News
Dr. Milisha Chotai Receives 2026 Global Recognition Award For Clinically Driven Preventive Dental Innovation
Dr. Milisha Chotai has been honored with a 2026 Global Recognition Award for Smile Boosters™, a dissolvable supplement designed for use between brushing. The award recognizes her evidence-based response to persistent gaps in everyday oral health care and its alignment with modern lifestyles. Photo Courtesy of Milisha Chotai Dr. Chotai received the award in the innovation and startup of the year category for advancing a structured approach to preventive dental care. Drawing on more than two decades of clinical experience, she identified a critical gap in traditional oral hygiene guidance: the extended periods between brushings, during which teeth are repeatedly exposed to food, drink, and environmental factors. Smile Boosters™ was developed as a practical, chairside-informed solution that integrates seamlessly into daily routines without requiring disruption or access to a sink. Her work reflects a broader shift in preventive care, where effectiveness is increasingly measured by how well solutions fit into contemporary habits shaped by frequent snacking, varied diets, and demanding schedules. Clinical Foundations And Professional Path Dr. Chotai’s career combines clinical practice, leadership, and education. As owner and principal dental surgeon at Newnham Dental Practice in Cambridgeshire, she oversees multidisciplinary teams and manages complex restorative and implant cases. Her role requires consistent attention to clinical outcomes, operational processes, and team development. She also contributes to academic advancement as a past honorary lecturer in dental implantology at the University of Bristol, reinforcing her commitment to evidence-based practice and knowledge sharing. Her academic credentials include an MSc in Dental Implantology and an MSc in Medical Education, as well as business certifications from Harvard Business School Online. This combination allows her to bridge clinical rigor with practical implementation, ensuring innovations like Smile Boosters™ are both scientifically grounded and viable in real-world settings. Extensive patient interactions, case studies, and clinical observations shaped the product’s development. Dr. Chotai identified a recurring pattern: patients who adhered to standard brushing advice still experienced preventable issues. By reframing the “between brushing” period as central rather than incidental, she positioned oral supplements as a meaningful extension of daily care. Innovation In Everyday Oral Care Traditional oral care models focus heavily on brushing moments, often overlooking the continuous exposure teeth face throughout the day. Dr. Chotai addressed this limitation by developing a dissolvable supplement that delivers fluoride and xylitol in a convenient, on-the-go format. Designed with patient behavior in mind, Smile Boosters™ enhances existing habits rather than requiring new ones. This approach aligns with growing 2026 industry trends favoring preventive solutions that integrate effortlessly into daily life, improving adherence and long-term outcomes. “Preventive strategies need to reflect how people live now, where time and environment influence consistency more than intention,” Dr. Chotai noted, highlighting the practical foundation behind the product. Global Recognition Awards judges evaluated her submission using criteria such as novelty, market impact, and ability to address global challenges. Her entry achieved top scores across innovation categories. The organization applies the Rasch model to convert evaluations into a standardized measurement scale, enabling consistent comparisons across industries. Final Words “Dr. Milisha Chotai’s work demonstrates how careful clinical insight can inform practical solutions that fit into everyday life,” said Alex Sterling, spokesperson for Global Recognition Awards. Her recognition underscores the importance of translating clinical expertise into accessible tools that improve patient outcomes. By focusing on the often-overlooked hours between brushing, Chotai has helped reshape preventive care frameworks while maintaining a strong foundation in established science. “The ability to connect rigorous clinical practice with accessible, everyday solutions is exactly what this award seeks to recognize,” Sterling added. Dr. Chotai’s journey from clinician to innovator remains rooted in prevention, addressing oral health issues before they become irreversible. Smile Boosters™ encourages both professionals and patients to consider the full daily cycle of oral care, supporting a shift toward more realistic and effective preventive strategies. About Global Recognition Awards Global Recognition Awards is an international organization that honors individuals and companies making meaningful contributions to their industries. Its evaluation framework emphasizes measurable impact, sustained commitment, and the potential to influence broader practices across sectors.
New: Survival Skills for Women’s Health Fall 2026 - Experts Teach Menopause
Novadose & Pure Pharmaceuticals Driving the Future of Peptide Science
Most Utah Deaths Never Reach the State Medical Examiner. Postmortem Pathology Offers Salt Lake City Families a Private Autopsy Option.
- July 24, 2026Medicine & Pharmaceuticals
Ace Therapeutics Introduces Validated Custom Animal Models to Support Cardiac Ischemia-Reperfusion Research
Global preclinical CRO Ace Therapeutics expands its cardiovascular disease model portfolio with fully validated myocardial ischemia-reperfusion (MI/R) animal modeling services, equipping academic labs and biopharma developers with reproducible research tools to advance ischemic cardiomyopathy therapeutic discovery. Surgical coronary artery ligation remains the gold-standard method to recapitulate human heart attack and reperfusion therapy pathology. Ace Therapeutics optimizes every procedural step for consistent, customizable model generation. Under deep anesthesia, Ace Therapeutics’ experts perform thoracotomy, temporary ligation of the left anterior descending coronary artery, timed ischemia incubation, suture release for reperfusion, followed by chest closure and layered skin closure. Post-operative continuous animal monitoring mitigates infection, organ failure, and premature mortality, ensuring intact study cohorts for long-term efficacy and mechanistic readouts. The custom coronary artery ligation MI/R models cover a broad panel of validated animal strains to match diverse research design requirements, including C57BL/6 and BALB/c mice, SD and Wistar rats, alongside New Zealand white and Japanese white rabbits. Rigorous multi-layered model validation protocols guarantee a reliable ischemic injury phenotype: real-time intraoperative ECG monitoring tracks ST-segment elevation as an immediate marker of successful coronary occlusion, while terminal myocardial tissue harvest paired with TTC-Evans blue dual staining enables precise quantitative calculation of infarct area, delivering objective histological endpoints for drug comparison. As scalable preclinical anti-ischemic drug efficacy evaluation models, these MI/R models support full-spectrum research workflows ranging from basic mechanistic pathway exploration to candidate compound pharmacodynamic screening. Researchers leverage the standardized surgical models to investigate signaling pathways governing ischemic preconditioning and reperfusion cytoprotection, quantify drug-mediated reductions in infarct size, and assess therapeutic impacts on oxidative stress, inflammatory signaling, and cardiomyocyte survival. All modeling procedures align with published cardiovascular research frameworks and peer-reviewed experimental protocols, delivering comparable, publication-quality datasets for preclinical IND-enabling studies. Ace Therapeutics has long specialized in custom cardiovascular disease animal model development, maintaining a full-service platform spanning atherosclerosis, hypertension, thrombosis, heart failure, and now refined MI/R injury systems. The launch of its standardized validated custom MI/R models fills a critical gap for partners seeking turnkey, validated preclinical anti-ischemic drug efficacy evaluation models without the resource burden of in-house surgical model optimization. Its integrated service package covers full model construction, intraoperative physiological monitoring, post-operative animal care, tissue collection, histochemical staining, and quantitative infarct analysis, streamlining end-to-end cardiovascular preclinical testing. Investigators and pharmaceutical developers focused on myocardial protection, anti-infarction, and reperfusion injury therapies can access Ace Therapeutics' complete animal models of cardiovascular disease for customized study design. Its cross-disciplinary team of cardiovascular pharmacologists, veterinary surgeons, and pathologists tailors model parameters—including ischemia duration, reperfusion timeline, and species selection—to match unique research hypotheses and drug development milestones. About Ace Therapeutics Ace Therapeutics is a leading provider of cardiovascular basic research services and custom preclinical animal model development. Its comprehensive disease model library enables translational research and drug efficacy assessment for ischemic heart disease, metabolic cardiovascular disorders, and chronic heart failure, supporting global academic institutions, biotech startups, and pharmaceutical enterprises in advancing novel cardiovascular therapeutics.
- July 23, 2026Medicine & Pharmaceuticals
Reputation House Published Sector-Wide Analysis of Digital Reputation Across Leading U.S. Pharma Companies
Reputation House has released its digital risk report for the pharmaceutical sector, a sector-wide analysis of digital reputation across 17 leading companies with a significant U.S. market presence. Each company was assessed using Risk Check, Reputation House's free AI-powered diagnostic platform, which maps how controllable a company's digital presence is across media and social channels, search results, AI-generated interpretations, and consumer trust signals. The report finds that digital reputational risk in pharma is structural rather than episodic. It is shaped less by current crises than by accumulated legal history, fragmented brand identity, and the growing influence of AI-generated content on how a brand is perceived. Across the 17 companies, the average Composite Risk Score is 33 out of 100, where a higher score indicates greater exposure. That places the sector average just above the boundary between the LOW and MEDIUM bands. Eleven companies landed in MEDIUM and six in LOW, with a high of 42 and a low of 24. "For years, pharmaceutical companies have invested in managing search results and press coverage, and those investments still matter. But a new discovery surface has emerged. When a patient, an investor, or a journalist asks an AI system about a company today, the answer often leans on decades of indexed regulatory and litigation history rather than on where the company stands now. That gap between how a company presents itself and how AI describes it is the reputational challenge of this decade, and it's one that traditional communications was never built to address. We built Risk Check so companies can finally see that problem and act on it," said Kristina Shinkareva, CEO of Reputation House. The most striking result concerns AI. Every company scored MEDIUM on AI Perception – the dimension that measures the gap between how a company positions itself and how AI systems like ChatGPT, Gemini, and Perplexity describe it. At this sample size, the metric doesn't yet differentiate between companies, so the report treats this as an early-stage, observational signal rather than a settled finding. But the pattern is clear enough to act on. AI systems draw heavily on the most authoritative and most heavily indexed sources – encyclopedias, news archives, government and litigation records — and for pharmaceutical brands that material disproportionately reflects regulatory actions, warning letters, pricing lawsuits, and historical controversies. Even companies with otherwise strong digital profiles inherit this framing. The legal matter may be long resolved; the digital signal persists. This is the central takeaway of the report. As AI becomes a primary discovery surface for patients, investors, and journalists, companies face a new category of risk that traditional PR and search-optimization frameworks were never built to measure: the gap between institutional reputation and AI-mediated perception. Alongside it, the report identifies brand-identity fragmentation – from spinoffs, name collisions, and subsidiary confusion – as a persistent, cross-channel vulnerability that AI systems tend to amplify rather than resolve. The full report is available at the official website of Reputation House . About Reputation House Reputation House is an international technology company specializing in digital risk protection. Our product combines a proprietary platform, an expert team, and an independent research division into a single solution for monitoring and controlling digital reputation risks before they become business losses. Official website: https://reputation.house About Risk Check RiskCheck is a free diagnostic platform that allows companies to assess their level of digital risk in just a few minutes and understand how stable their information environment really is. Available at: https://checkmyrisks.com Full Report direct link: https://rc.reputation.house/pharma-reputation-risk-research-2026
- July 23, 2026Medicine & Pharmaceuticals
Flavettes Celebrates Healthcare Heritage in Merdeka 2026 Campaign
Duopharma Biotech Berhad ("Duopharma Biotech" or "the Company") officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik. The launch event saw the attendance of Zuraini Abdul Ghani, Director of Package Development Division, Tourism Malaysia; Wan Amir-Jeffery Wan Abdul Majid, Group Chief Executive Officer, Duopharma Biotech; Noor Aida Jaafar, Chief Commercial Officer, Duopharma Biotech; Foo Hwei Jiek, Trading Director, Watsons Malaysia; Ekram Faiz, Director and Co-Founder, Kapten Batik; and Farhan Omar, Director and Co-Founder, Kapten Batik. Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid remarked, “At Duopharma Biotech, we’re proud that Flavettes has been trusted by generations of Malaysians to support their health and wellness, captured in our Merdeka 2026 campaign theme ‘Flavettes Setia Menemani Setiap Generasi’. Today, after more than 30 years in the market, Flavettes offers more than just immunity support. In line with Duopharma Biotech’s aim of Providing Smarter Solutions for a Healthier Life, the brand has grown to include a wider Halal-certified portfolio of health, wellness, beauty, and skincare solutions, in various formats such as effervescent, chewable and powder in sachets, to suit the different lifestyles and preferences of modern consumers looking for a more holistic approach to well-being.”
- July 22, 2026Medicine & Pharmaceuticals
PUKO Nutrition Launches Focus + Drive: A Two-Speed Nootropic for Clean Energy Now and Brain Support That Builds Over Weeks
PUKO Nutrition , a U.S. direct-to-consumer company focused on cognitive performance, today announced the nationwide launch of PUKO Focus + Drive, a daily nootropic supplement designed to support mental energy on two timelines: within the hour, and over the weeks that follow. It is the first stage of a three-part system that treats daytime focus and nighttime recovery as two halves of the same cognitive engine. The flagship pairs slow-release guarana with clinically studied phosphatidylserine at fully disclosed doses to support mental energy through the workday. Two melatonin-free night formulas carry the same system into sleep, the brain's window for recovery and long-term nutrition. Focus + Drive takes a different route. Each two-capsule serving pairs 200 mg of guarana extract, a plant caffeine source whose gradual release comes from caffeine naturally bound to tannins and fiber, with 60 mg of phosphatidylserine, a structural phospholipid of brain cell membranes that supports healthy cognitive function and brain cell communication.The guarana supports alertness and reaction time within 30 to 60 minutes, while the phosphatidylserine builds cognitive support over four to six weeks of consistent daily use.* Both doses are printed in full on the label, with no proprietary blends and no synthetic caffeine. "Most energy products sell a stronger hit. We built a base that compounds," the company said in a statement. "Guarana gives you clean mental energy this afternoon, and phosphatidylserine supports memory and attention over weeks of daily use.* Energy is the entry point. Thinking performance is the goal." The second stage of the system is sleep, and PUKO approaches it as brain infrastructure rather than a separate category. During deep, slow-wave sleep the brain naturally consolidates the day's learning into memory and clears the metabolic byproducts of a full day of thinking. That is why the CDC's finding that more than one in three U.S. adults does not get enough sleep is as much a performance problem as a health one.PUKO's two night formulas support that overnight window without synthetic melatonin. PUKO Unwind + Sleep KSM-66 combines 240 mg of magnesium glycinate chelate, 200 mg of KSM-66® ashwagandha extract standardized to 5% withanolides, and 150 mg of lemon balm extract to support evening wind-down and the body's response to everyday stress.* PUKO Deep Sleep + Recovery pairs 240 mg of magnesium glycinate chelate with Montmorency tart cherry powder, a natural source of melatonin precursors, and saffron extract to support deep, restorative sleep and long-term brain nutrition through consistent overnight recovery.* Both are non-habit forming. "Better sleep is the most underrated layer of cognitive performance," the company added. "The daytime capsule supports the hours you spend thinking. The night formulas support the hours your brain uses to consolidate what you learned and restock for tomorrow. That is why we built them as one staged system instead of separate products." The full system is available now at pukonutrition.com. ABOUT PUKO NUTRITION PUKO Nutrition is a U.S. direct-to-consumer supplement company founded in 2022. Its staged three-formula system supports daytime focus and deep, restorative sleep as the foundation of long-term cognitive performance. All formulas are non-habit forming and third-party tested, the sleep formulas contain no synthetic melatonin, and every label discloses the exact dose of every active ingredient. Learn more at https://pukonutrition.com .
- July 21, 2026Medicine & Pharmaceuticals
"Grandpa Sugar Pill" Honored at UNESCO Headquarters Centenary Commemoration of Gu Fangzhou Held in France
On July 16, the launch ceremony of the event themed A Century of Legacy, A Future of Shared Prosperity – Commemorative Event for the 100th Anniversary of the Birth of Gu Fangzhou was held at UNESCO Headquarters in Paris. Jointly organized by the China Association for Science and Technology, the National Commission of the People's Republic of China for UNESCO, and the Permanent Delegation of the People's Republic of China to UNESCO, the activity gathered more than 100 representatives from UNESCO, permanent delegations of Cambodia, Italy and other countries to UNESCO, the Institut Pasteur, the Accademia Nazionale dei Lincei, as well as top Chinese and foreign universities and public health research institutions. This international exchange platform served to celebrate the spirit of scientists, showcase the commitment and sense of duty of Chinese medical science and technology workers, and share the compelling stories of Chinese scientists with a global audience. Gu Fangzhou (1926–2019) was a distinguished Chinese virologist. He led the research and development of oral poliovirus vaccine, widely known as the "sugar pill", which protected hundreds of millions of Chinese children from poliomyelitis and earned him the affectionate title "Grandpa Sugar Pill". Under his leadership, China attained the polio-free certification in 2000. Moreover, he shared China’s mature large-scale immunization experience and low-cost vaccine technologies with developing countries, creating an exemplary model for South-South health cooperation. The launch ceremony featured keynote speeches from distinguished guests. H.E. Ms Yang Xinyu, Ambassador, Permanent Delegate of the People's Republic of China to UNESCO, attended and delivered an address. Speeches were delivered by Abou Amani, Assistant Director-General for Sciences, a.i., UNESCO; H.E. Mr Kosal Long, Ambassador Extraordinary and Plenipotentiary, Permanent Delegate of the Kingdom of Cambodia to UNESCO; Professor Maria Vittoria Cubellis from the Permanent Delegation of the Republic of Italy to UNESCO, alongside representatives of other national permanent delegations. Dr. LUO Hui, Executive Secretary for International Affairs and Strategy Research, China Association for Science and Technology, delivered a speech and officially opened the commemoration ceremony, witnessing this important moment together with all attendees. In her remarks, Luo said CAST, China's largest organization representing science and technology professionals, co-organized the commemorative events with UNESCO to highlight the significance of Gu's legacy for today's world. She said technological innovation should serve humanity, scientific achievements require sustained commitment, research should be guided by ethical principles, and human progress depends on international exchanges and mutual learning. Abou Amani stated that Gu Fangzhou’s life story can stimulate young people’s interest, curiosity and aspiration for science. UNESCO intends to deepen cooperation with CAST and other relevant institutions, with a focus on science popularization, improving public scientific literacy and science education. The two sides will jointly build exchange platforms and hold thematic exhibitions to bring science closer to the public and encourage more young people to engage in scientific careers. Yang Xinyu pointed out that humanity is currently facing shared challenges including emerging infectious diseases, climate change, biodiversity loss and technological transformation. Gu Fangzhou’s philosophy aligns closely with the core mission of UNESCO. His life experience tells us that science can realize its greatest value only through knowledge sharing, strengthened multilateral cooperation, and universal access to innovative scientific achievements. During the scientific and cultural exchange session, Mr Gu Lienan, second son of the late Dr. Gu Fangzhou, delivered remarks and recounted touching stories of his father’s lifelong dedication to polio prevention and treatment. A panel of Chinese and foreign experts held thematic academic dialogues focusing on cutting-edge immunology and vaccine development research. The speakers include: Chu Yiwei, Vice President, Chinese Society for Immunology; President, Shanghai Society for Immunology; Aleksandra Deczkowska, Research Expert, Department of Immunology and Neuroscience, Institut Pasteur (France); Wang Jin, Professor of Neurosurgery at Tsinghua University and the Washington University School of Medicine; Véronique Briquet-Laugier, PhD in Biophysics, Senior Manager of Scientific Affairs, Agence Nationale de la Recherche (ANR), France. In December 2025, the 43rd Session of the UNESCO General Conference formally approved the inclusion of the Commemorative Event for the 100th Anniversary of the Birth of Gu Fangzhou in UNESCO’s official programme for 2026–2027. Hosting this commemoration at UNESCO Headquarters stands as full recognition from the international community of Gu Fangzhou’s outstanding scientific contributions and noble humanistic spirit, as well as a key initiative to boost exchanges and mutual learning within the global public health sector. From "Grandpa Sugar Pill" Gu Fangzhou to the enduring spiritual legacy of the "People’s Scientist", the touching stories of Chinese medical science and technology workers devoting their entire lives to safeguarding human health keep spreading across the global stage.
- July 20, 2026Medicine & Pharmaceuticals
CD BioSciences Launches Custom Zebrafish Aging Model Services to Accelerate Anti-Aging and Geriatric Drug Discovery
CD BioSciences unveiled a complete portfolio of tailored zebrafish (Danio rerio) aging model development and analytical services, addressing rising global demand for robust in vivo platforms to dissect aging biology, age-related cognitive decline, and therapeutic interventions for degenerative disorders. Against a backdrop of extended human lifespans and limited understanding of long-term anti-aging therapeutic efficacy, zebrafish have emerged as a gold-standard preclinical organism. The species undergoes gradual aging that parallels human physiological and behavioral shifts, paired with mature molecular and genetic toolkits to decode cellular drivers of age-associated cognitive impairment. CD BioSciences’ newly expanded service suite integrates genetic, dietary, and pharmacological aging induction strategies, delivering flexible, reproducible model systems for academic labs and pharmaceutical drug developers alike. Leveraging Tol2 transposon insertional mutagenesis alongside CRISPR-Cas9 genome editing, CD BioSciences generates CRISPR-Cas9 transgenic zebrafish aging models with either accelerated or prolonged lifespans. Researchers can precisely modulate conserved longevity signaling axes including sirtuin pathways, insulin/IGF-1 cascades, and cellular senescence programs. Complementary transient gene modulation tools, such as Morpholino antisense oligonucleotides and in vitro transcribed capped mRNA microinjection, are also available for embryonic and adult-stage target gene silencing, enabling granular functional validation of aging-related genes. Complementing genetically modified lines, CD BioSciences engineers pharmacologically-induced and diet-induced premature senescence zebrafish to recapitulate environmentally driven aging phenotypes. For dietary induction, customized high-calorie, high-fat, or nutrient-deficient feeding regimens reliably trigger early senescence and the full spectrum of age-linked pathological traits. Pharmacological aging induction relies on well-characterized agents including rapamycin, allowing controlled onset of aged physiological states without permanent genomic alteration. This dual induction system lets clients disentangle environmental and genetic contributions to senescence, supporting mixed-factor disease modeling that mirrors the multifactorial origins of human age-related illnesses. Beyond model construction, CD BioSciences delivers end-to-end phenotypic profiling workflows. Comprehensive quantitative assays and in vivo imaging pipelines quantify age-related changes spanning physical function, cognitive performance, tissue histopathology and senescence biomarkers, tracking the progressive timeline of aging at cellular and organismal levels. The customizable platforms further support complex age-related disease modeling, combining genetic, dietary, and pharmaceutical triggers to recapitulate neurodegenerative, cardiovascular, and other late-onset pathologies for translational research. With decades of collective expertise in aquatic model organism engineering and geroscience research, CD BioSciences unifies model generation, phenotypic analysis, and translational drug testing under one integrated service pipeline. All generated zebrafish aging models and supporting analytical assays are exclusively for preclinical laboratory investigation. Researchers and pharmaceutical developers seeking custom aging model solutions can directly contact CD BioSciences’ technical support team for project consultation. About CD BioSciences CD BioSciences is a leading global supplier of tailored preclinical animal model development, molecular biology testing, and translational research services. It specializes in custom aging, disease and transgenic model systems across multiple aquatic and mammalian species, supporting target validation, mechanism exploration, and small-molecule therapeutic screening for academic, biotech, and pharmaceutical partners worldwide.
- July 20, 2026Medicine & Pharmaceuticals
Protheragen Rolls Out Full-Spectrum Integrated API Services Covering Synthesis, Contract Manufacturing and End-to-End Testing
Protheragen, a specialized service provider focused on Active Pharmaceutical Ingredient (API) development and manufacturing, unveils its fully integrated suite of API services, combining API synthesis, scalable API contract manufacturing, and full-scope API testing to streamline drug R&D and commercialization for pharmaceutical enterprises worldwide. Active Pharmaceutical Ingredients form the therapeutic core of all medicines, spanning oral capsules, injections, topical creams, and other finished dosage forms. As drug development pipelines grow more complex across small molecules, peptides, nucleic acids, and natural-derived therapeutics, pharma developers face mounting pressure to secure reliable, compliant partners capable of handling every stage from molecular design to commercial production and quality verification. Protheragen’s unified services address this industry pain point by eliminating fragmented third-party collaboration and delivering consistent regulatory-aligned outcomes across the entire API lifecycle. Protheragen’s core offering lies in its custom API synthesis service , staffed by a cross-disciplinary team of organic chemistry specialists with deep expertise in designing cost-effective, scalable synthetic pathways for diverse API categories. The platform supports organic, inorganic, and biosynthesis workflows, covering small-molecule drugs, protein and peptide therapeutics, nucleic acid gene therapy APIs, natural extract-based compounds and synthetic biology-derived molecules. The standardized API synthesis workflow encompasses route design, raw material pretreatment, multi-step controlled reactions, multi-technique purification, and stage-by-stage quality control via HPLC, NMR, and mass spectrometry, ensuring high yield, purity, and minimal impurity generation for lab-scale to pre-commercial batches. Complementing its lab-scale synthesis capacity, Protheragen delivers full-lifecycle API contract manufacturing as an end-to-end outsourced production solution. The service spans initial project consultation, customized process development, pilot scale-up, cGMP-compliant commercial manufacturing, and complete batch documentation delivery. Operating within state-of-the-art production facilities, Protheragen executes strict quality and regulatory adherence throughout all production phases, furnishing clients with transparent progress reporting, full reaction schematics, intermediate analytical records, and final quality certificates upon order completion. For each production campaign, residual intermediate samples are retained for one year to support future regulatory audits, offering pharmaceutical partners a stable, traceable API supply for clinical and commercial launch stages. In addition to API synthesis and API contract manufacturing, Protheragen also offers API stability testing to validate safety, efficacy, and shelf-life compliance, forming a critical quality control pillar of Protheragen’s service ecosystem. Its API stability testing covers three standardized trial tiers: influence factor tests (high temperature, high humidity and strong light exposure for 10 days), 6-month accelerated stability trials, and 12-month long-term storage evaluations under industry-standard temperature and humidity conditions to define product expiry, degradation pathways, and optimal packaging specifications. Beyond stability assessment, its API testing suite extends to stress testing under extreme pH, heat and light, physical characteristic profiling (particle size, crystal polymorphism, solubility), impurity risk evaluation, and excipient compatibility studies to prevent formulation incompatibilities in final drug products. Beyond these core offerings, Protheragen provides supplementary technical support including manufacturing process validation, technology transfer from laboratory to commercial scale, and customized analytical method development tailored to unique molecular structures. All operations align with global pharmaceutical regulatory standards, prioritizing impurity control, batch consistency, and data integrity for clients targeting global market authorization. About Protheragen Protheragen is a global API service provider specializing in end-to-end Active Pharmaceutical Ingredient solutions, with core strengths in API synthesis, API contract manufacturing, and comprehensive API testing. Equipped with advanced laboratory and production infrastructure and a team of seasoned pharmaceutical chemists and analytical scientists, Protheragen delivers scalable, regulatory-compliant API development and manufacturing services covering pre-clinical research through commercial-scale production.
- July 14, 2026Medicine & Pharmaceuticals
Creative Biolabs Expands Live Biotherapeutic Product Evaluation Services with Strain Persistence Analysis and Microbiome Biomarker Research
The newly integrated pipeline addresses the pharmaceutical industry's critical bottlenecks in microbiome-based drug development: quantifying in vivo strain persistence, deciphering systemic multi-organ mechanisms, and identifying clinical biomarkers for oncology immunotherapies. By bridging the gap between benchtop microbial discoveries and clinical-stage translational medicine, the platform provides a rigorous, data-driven framework to validate the pharmacological efficacy and safety of therapeutic live bacteria. Quantifying Microbial Pharmacokinetics via Strain-Level Engraftment Analysis A primary challenge in LBP development is verifying whether an introduced bacterial strain successfully colonizes the host microbiota. Traditional genus-level profiling frequently lacks the resolution to distinguish an exogenous therapeutic strain from endogenous lookalikes. Creative Biolabs' updated platform solves this through high-resolution metagenomic sequencing and strain-specific quantitative PCR. "Evaluating the therapeutic potential of any live bacterial strain requires absolute precision in tracking its dynamic fate within the complex host gut environment," stated a chief scientific officer at Creative Biolabs. "Our strain-level engraftment and persistence analysis empowers researchers to chart definitive microbial pharmacokinetic profiles, confirming whether a strain retains its functional viability over critical therapeutic windows." Deciphering Systemic Efficacy with Multi-Organ-on-Chip Models To bypass the physiological disparities inherent in traditional animal models, the platform integrates biomimetic microfluidic systems. These multi-organ-on-chip models for gut-liver and gut-brain axes help simulate the multicellular interfaces, shear stress, and biochemical signaling of human organs. This advanced framework allows biopharmaceutical developers to capture real-time data on metabolic crosstalk, gut barrier integrity, and neuro-immune interactions driven by microbial metabolites. Predicting Clinical Outcomes: Microbiome Biomarker Strategies in Oncology Beyond mechanism validation, the platform extends directly into translational oncology. Accumulating clinical data indicates that a patient's baseline gut microbiome significantly modulates their clinical response to Immune Checkpoint Inhibitors (ICIs), such as anti-PD-1 therapies. Creative Biolabs provides a comprehensive translational microbiome biomarker strategy for ICI response . By pairing baseline microbiome multi-omics data with advanced machine learning classifiers, the strategy successfully segregates potential clinical "responders" from "non-responders." This methodology provides clinical trial sponsors with actionable tools for robust patient stratification and the co-development of microbiome-based companion diagnostics. Technical Reference & Availability The newly consolidated LBP preclinical evaluation platform is fully operational and compliant with current international regulatory guidelines for microbiome therapeutics development. Biopharmaceutical innovators, academic institutes, and clinical research organizations looking to mitigate development risks and optimize their live biotherapeutic pipelines are invited to discover the full technical specifications of these solutions. To explore how these advanced analytics can elevate your current pipeline or to request a detailed technical consultation with a microbial specialist, visit Creative Biolabs Live Biotherapeutics Platform.
- July 13, 2026Medicine & Pharmaceuticals
Amerigo Scientific Announces Residue Detection Kits, Advancing Life Science Research and Ensuring Pharmaceutical Safety
Amerigo Scientific, a trusted supplier of laboratory and analytical solutions for the life science and biotech industries, has unveiled an extensive portfolio of professional residue detection kits to address the growing demand for precise contaminant testing in biopharmaceutical development, bioprocessing, and scientific research. These ready-to-use kits are engineered to identify trace harmful residues and impurities, safeguarding product safety, research accuracy, and regulatory compliance across diverse laboratory and manufacturing workflows. Biologics, including therapeutic antibodies, vaccines, growth factors as well as cell and gene therapies, are vital modern medical products derived from microorganisms, plants, or animal cells. Their intricate production processes are prone to various contaminations such as residual solvents, viruses, and stray DNA, which may undermine product safety, therapeutic efficacy and adherence to industry regulations. Residue detection has therefore become an indispensable quality control step throughout the entire industrial chain of life sciences and biopharmaceuticals. Designed to meet stringent standards for high sensitivity, reliability, and efficiency, the residue detection kits from Amerigo Scientific deliver rapid and accurate testing results. Its product range covers multiple testing scenarios: residual solvents and endotoxins for pharmaceutical development, DNA and protein residues for bioprocessing, and impurities in lab-grade water and reagents. Featuring user-friendly operation and versatile adaptability, these kits serve as core tools to drive continuous progress in scientific and medical innovation. From routine laboratory testing to rigorous quality control for biologic products, Amerigo Scientific’s residue detection kits are tailored to satisfy the strict requirements of research and development institutions and biopharmaceutical enterprises worldwide. In addition to residue detection kits, Amerigo Scientific also offers unique adeno-associated virus (AAV) quantification ELISA kits for total AAV capsid determination in gene therapy research and development, chemiluminescence immunoassay (CLIA) kits for the quantitative detection of multiple trace substances, such as antigens, antibodies, and hormones. PCR kits, protein labeling kits, and nucleic acid purification & quantification kits are also available at Amerigo Scientific. About Amerigo Scientific Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation from all companies and institutions in the area of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers’ questions or concerns and are always ready to provide individualized customer service of high standards.
- July 13, 2026Medicine & Pharmaceuticals
Ace Therapeutics Expands Specialized Preclinical Respiratory CRO Services to Accelerate Respiratory Drug Development
Ace Therapeutics, a globally recognized preclinical contract research organization (CRO), reinforces its leadership in respiratory drug research by delivering tailored and reliable preclinical respiratory CRO services to pharmaceutical enterprises, academic institutions, and research groups across the world, aiming to streamline the entire preclinical development journey for novel respiratory therapeutics. Respiratory disorders including asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and refractory cough continue to pose substantial unmet medical needs globally, driving rising demand for rigorous preclinical research to validate candidate drugs before clinical translation. As a dedicated preclinical research partner, Ace Therapeutics has built a full-spectrum service portfolio centered on respiratory disease research, with in vivo respiratory disease models standing as one of its core technical strengths. Ace Therapeutics has established a diverse panel of well-validated animal models covering multiple species such as mice, rats, guinea pigs, and rabbits, which accurately recapitulate the pathological features, inflammatory mechanisms, and physiological responses of human respiratory conditions. These models support in-depth mechanistic exploration, efficacy evaluation, and safety assessment for therapies targeting airway inflammation, cough reflex, lung tissue remodeling, and other key pathways, generating highly translational data for clients’ research projects. Beyond the development of in vivo respiratory disease models, Ace Therapeutics provides integrated solutions including in vitro compound screening, inhalation delivery system optimization, pharmacokinetic analysis, efficacy testing, and comprehensive biomarker analysis. Supported by state-of-the-art laboratory facilities and a team of seasoned scientists with extensive experience in respiratory research, Ace Therapeutics customizes study protocols based on clients' unique research objectives, whether for early target validation, lead compound screening, or large-scale preclinical proof-of-concept studies. All research activities adhere to international quality and ethical standards, ensuring the reproducibility and credibility of experimental results. For researchers and drug developers focusing on respiratory treatments, selecting appropriate animal models and professional CRO support are critical to shortening R&D cycles and lowering project risks. Ace Therapeutics' flexible service mode enables seamless collaboration with clients at every research stage. From designing customized in vivo respiratory disease models for specific disease phenotypes to executing end-to-end preclinical testing, Ace Therapeutics strives to remove technical barriers and accelerate the progression of promising respiratory drug candidates toward clinical trials. With a growing footprint across North America and Europe, Ace Therapeutics continues to upgrade its technical platforms and expand its model library for respiratory diseases. It remains committed to advancing preclinical respiratory research, and will keep optimizing its service system to support more breakthroughs in the field of respiratory therapeutics in the long run. About Ace Therapeutics Ace Therapeutics is a professional preclinical CRO focusing on one-stop preclinical research services. Its service scope spans efficacy assessment, toxicology research, pharmacokinetic analysis, model development, and biomarker research across multiple therapeutic areas. Rooted in rigorous scientific standards and innovative technologies, Ace Therapeutics serves global clients from biotech firms and large pharmaceutical companies to academic research labs, dedicating to driving the efficient development of new drugs and novel therapies.
- July 8, 2026Medicine & Pharmaceuticals
Generic Peptides Reworks Its Research Peptide Catalog to Make Online Comparison Easier for U.S. Buyers
The company is pairing structured product categories with educational content, practical tools, and domestic shipping to reduce confusion in online research peptide shopping. Buying research peptides online can be confusing. Product names often look similar, categories are not always explained, and buyers may have to move between product pages, forums, and technical sources just to understand what they are comparing. Generic Peptides is working to make that process easier. The U.S.-focused supplier has structured its online product range into nine research-focused categories and added practical website tools as part of a broader update to its shopping experience. The goal is to give research-use buyers a more direct way to browse products, compare categories, read educational content, and move through checkout with fewer unclear steps. A Catalog Built Around Comparison Instead of presenting products as one long list, Generic Peptides groups its catalog by research area. The site includes categories for longevity research, metabolism, recovery, cognitive and neurological research, endocrine research, cosmetic and skin-related research, and blended product categories. That structure is meant to help buyers start with a broad area of interest and narrow their search without getting lost in unrelated listings. Education Without Medical Claims Generic Peptides also publishes educational articles and news-style updates written in plain language. The content is designed to help visitors understand peptide-related topics without presenting products as treatments, cures, or consumer health solutions. The company states that its products are intended for research use only and are not for human use. That position shapes how the website presents product information, category pages, and educational resources. Tools for a Cleaner Buying Process Alongside its catalog and educational content, Generic Peptides focuses on giving visitors a cleaner website experience: structured navigation, secure checkout, domestic shipping, and straightforward ordering information. For customers comparing suppliers online, those details can matter as much as product availability. A product page may answer one question, but the full buying experience depends on how easily a visitor can compare options, understand the category, and complete an order without confusion. Why the Update Matters The research peptide market is crowded, and many websites still rely on short product listings with limited context. Generic Peptides is taking a different approach by combining product access with category structure, educational support, and a more transparent shopping process. The company says it plans to continue improving product presentation, expanding educational content, and strengthening navigation across the website. For more information, visit https://genericpeptides.com/ Educational resources are available at https://genericpeptides.com/articles About Generic Peptides Generic Peptides is a U.S.-focused online supplier of research peptides and related compounds. The company provides structured product categories, educational resources, secure checkout, and domestic shipping for research-use customers. Buy USA-Made Research Peptides Online | 99% HPLC | Generic Peptides Premium research peptides made in the USA. 99% purity, batch-linked COA available, 3-7 day shipping. Trusted by researchers since 2019, Generic Peptides offers a wide selection of research-use compounds, educational resources, and a streamlined online ordering experience designed for U.S. buyers. Products are intended for research use only and are not for human consumption. Company Details: Company Name: Generic Peptides Contact Person: George Email: [email protected] Website: https://genericpeptides.com/
ALL NEWS
- AI Search Optimization For SMBs: ChatGPT Overview Visibility Strategy Announced
- Lindfield's North Shore Smiles Champions Everyday Oral Care Habits for Dental Health Week 2026
- Ronbow Named Among the Best Custom Cabinet Makers for High-End Kitchen Renovations in 2026
- It Is Your Story to Tell Celebrates Three Years of Transforming Lives and One Year as an Official 501(c)(3) Nonprofit
- Colfax Pizza Party Package For Girlfriend Day Hangout: Carryout Deals Announced
- Kennedy University Secures IKCA Accreditation to Enhance International Workforce Utility
- SEAMEO 60th Anniversary Forum Held in Guiyang to Advance Regional Education Cooperation
- SEAMEO TED Cooperation Forum Held in Guiyang to Advance Regional Technical Education Collaboration
- VdoCipher Launches Free Video Compressor for Large Video Files upto 10 GB
- Geely Auto Group Reports 250,161 Vehicle Sales in July
- Lotus Endometriosis Institute Announces Post-Op Recovery Plans For Endo Patients
- Soap-Free Carpet & Upholstery Cleaner For Pet Stains & Spills Launched
- Boris Mizhen - Proud To Attend NMHC Apartment Strategies Outlook Conference
- Why Restoration Companies Need Story Content to Win Trust - Guide Released
- How to Increase Roofing Profit Per Job Without Raising Prices | New Guide
- Harmony Care Finder Launches Free Concierge Service to Simplify ABA Therapy and Autism Care Matching for Families
- Elevon Partners Launches Research Initiative to Reframe Private Market Opportunities
- Shanghai Xiongda International Logistics Unveils Expansive 10,000-Square-Meter Headquarters Warehouse to Streamline Global E-Commerce Supply Chains
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS